JP2020121985A5 - - Google Patents

Download PDF

Info

Publication number
JP2020121985A5
JP2020121985A5 JP2020068158A JP2020068158A JP2020121985A5 JP 2020121985 A5 JP2020121985 A5 JP 2020121985A5 JP 2020068158 A JP2020068158 A JP 2020068158A JP 2020068158 A JP2020068158 A JP 2020068158A JP 2020121985 A5 JP2020121985 A5 JP 2020121985A5
Authority
JP
Japan
Prior art keywords
medicament
weeks
manufactured
period
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020068158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020121985A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020121985A publication Critical patent/JP2020121985A/ja
Publication of JP2020121985A5 publication Critical patent/JP2020121985A5/ja
Pending legal-status Critical Current

Links

JP2020068158A 2015-07-08 2020-04-06 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物 Pending JP2020121985A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
US62/189,813 2015-07-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018520045A Division JP6752276B2 (ja) 2015-07-08 2016-07-07 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物

Publications (2)

Publication Number Publication Date
JP2020121985A JP2020121985A (ja) 2020-08-13
JP2020121985A5 true JP2020121985A5 (cg-RX-API-DMAC7.html) 2020-11-05

Family

ID=56373100

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018520045A Expired - Fee Related JP6752276B2 (ja) 2015-07-08 2016-07-07 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物
JP2020068158A Pending JP2020121985A (ja) 2015-07-08 2020-04-06 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018520045A Expired - Fee Related JP6752276B2 (ja) 2015-07-08 2016-07-07 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物

Country Status (21)

Country Link
US (3) US10413535B2 (cg-RX-API-DMAC7.html)
EP (1) EP3319639B1 (cg-RX-API-DMAC7.html)
JP (2) JP6752276B2 (cg-RX-API-DMAC7.html)
KR (2) KR102440162B1 (cg-RX-API-DMAC7.html)
CN (1) CN107921136A (cg-RX-API-DMAC7.html)
AU (1) AU2016290197B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018000112A2 (cg-RX-API-DMAC7.html)
CA (1) CA2989522C (cg-RX-API-DMAC7.html)
CL (1) CL2018000057A1 (cg-RX-API-DMAC7.html)
ES (1) ES2835274T3 (cg-RX-API-DMAC7.html)
HK (1) HK1247120A1 (cg-RX-API-DMAC7.html)
IL (2) IL256770B (cg-RX-API-DMAC7.html)
MA (2) MA42016A1 (cg-RX-API-DMAC7.html)
MX (1) MX385229B (cg-RX-API-DMAC7.html)
MY (1) MY187552A (cg-RX-API-DMAC7.html)
PL (1) PL3319639T3 (cg-RX-API-DMAC7.html)
RU (1) RU2018103940A (cg-RX-API-DMAC7.html)
TN (1) TN2017000538A1 (cg-RX-API-DMAC7.html)
UA (1) UA123728C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017006272A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708601B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165218A1 (en) 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
KR20220054598A (ko) * 2019-07-26 2022-05-03 알레그로 파마슈티칼스, 엘엘씨 비삼출성 황반변성 및 기타 안질환 치료용 펩티드
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4232458A4 (en) * 2020-10-21 2024-10-02 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
SI1881823T1 (sl) * 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Similar Documents

Publication Publication Date Title
JP7475395B2 (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
JP7116490B2 (ja) 眼の炎症性障害および疾患の組合せ処置
US20150133546A1 (en) Sustained release delivery of one or more agents
US12364685B2 (en) Isoxazoline parasiticide formulations
CA2899321C (en) Fluorinated .alpha..nu.integrin antagonists
US8299124B2 (en) Aqueous intraocular penetration-promoting eye drop
CN111182893A (zh) 包含f6h8的眼用组合物
US20140171490A1 (en) Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
JP6752276B2 (ja) 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物
BRPI0617414A2 (pt) mÉtodo para tratamento de formas primÁrias e secundÁrias de glaucoma
BR112020008046A2 (pt) composições e métodos de uso para tratamento de inflamação anormal em glândulas secretoras perioculares ou na superfície ocular
JP2009524692A (ja) ドライアイのための処方物および方法
JP2022523548A5 (cg-RX-API-DMAC7.html)
JP2020063269A (ja) 多発性硬化症を治療するための小児科の組成物
JP7571037B2 (ja) 眼表面疼痛を治療する方法
WO2019213330A1 (en) Liquid depot for non-invasive sustained delivery of agents to the eye
US20110257186A1 (en) Compositions and methods for treating visual disorders
US20160095861A1 (en) Ophthalmic ointments comprising valganciclovir hydrochloride for treating infective eye diseases